Literature DB >> 24136113

HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection.

Amber L Wheeler1, Rebecca Scherzer, Daniel Lee, Joseph A C Delaney, Peter Bacchetti, Michael G Shlipak, Stephen Sidney, Carl Grunfeld, Phyllis C Tien.   

Abstract

BACKGROUND: Higher levels of small low-density lipoprotein (LDL) and lower levels of high-density lipoprotein (HDL) subclasses have been associated with increased risk of cardiovascular disease. The extent to which HIV infection and HIV/hepatitis C virus (HCV) coinfection are associated with abnormalities of lipoprotein subclasses is unknown.
METHODS: Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy in plasma samples from 569 HIV-infected and 5948 control participants in the Fat Redistribution and Metabolic Change in HIV Infection (FRAM), Coronary Artery Risk Development in Young Adults (CARDIA), and Multi-Ethnic Study of Atherosclerosis (MESA) studies. Multivariable regression was used to estimate the association of HIV and HIV/HCV coinfection with lipoprotein measures with adjustment for demographics, lifestyle factors, and waist-to-hip ratio.
RESULTS: Relative to controls, small LDL levels were higher in HIV-monoinfected persons (+381 nmol/l, P <0.0001), with no increase seen in HIV/HCV coinfection (-16.6 nmol/l). Levels of large LDL levels were lower (-196 nmol/l, P <0.0001) and small HDL were higher (+8.2 μmol/l, P < 0.0001) in HIV monoinfection with intermediate values seen in HIV/HCV coinfection. Large HDL levels were higher in HIV/HCV-coinfected persons relative to controls (+1.70 μmol/l, P <0.0001), whereas little difference was seen in HIV-monoinfected persons (+0.33, P = 0.075). Within HIV-infected participants, HCV was associated independently with lower levels of small LDL (-329 nmol/l, P <0.0001) and small HDL (-4.6 μmol/l, P <0.0001), even after adjusting for demographic and traditional cardiovascular risk factors.
CONCLUSION: HIV-monoinfected participants had worse levels of atherogenic LDL lipoprotein subclasses compared with controls. HIV/HCV coinfection attenuates these changes, perhaps by altering hepatic factors affecting lipoprotein production and/or metabolism. The effect of HIV/HCV coinfection on atherosclerosis and the clinical consequences of low small subclasses remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24136113      PMCID: PMC4267724          DOI: 10.1097/QAD.0000000000000026

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  41 in total

1.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.

Authors:  W Timothy Garvey; Soonho Kwon; Deyi Zheng; Sara Shaughnessy; Penny Wallace; Amy Hutto; Kimberly Pugh; Alicia J Jenkins; Richard L Klein; Youlian Liao
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

2.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.

Authors:  Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas
Journal:  Atherosclerosis       Date:  2006-10-02       Impact factor: 5.162

3.  Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.

Authors:  M Duong; J M Petit; L Piroth; M Grappin; M Buisson; P Chavanet; P Hillon; H Portier
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

4.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection.

Authors:  Philippe Sosner; Marc Wangermez; Carine Chagneau-Derrode; Gwenaël Le Moal; Christine Silvain
Journal:  Atherosclerosis       Date:  2012-02-23       Impact factor: 5.162

6.  Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients.

Authors:  R Bedimo; A O Westfall; M Mugavero; H Drechsler; N Khanna; M Saag
Journal:  HIV Med       Date:  2010-02-15       Impact factor: 3.180

Review 7.  Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature.

Authors:  Torsten Roed; Anne-Mette Lebech; Andreas Kjaer; Nina Weis
Journal:  Clin Physiol Funct Imaging       Date:  2012-07-30       Impact factor: 2.273

8.  Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.

Authors:  Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

9.  Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials.

Authors:  Judith Hsia; James D Otvos; Jacques E Rossouw; LieLing Wu; Sylvia Wassertheil-Smoller; Susan L Hendrix; Jennifer G Robinson; Bernedine Lund; Lewis H Kuller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-03       Impact factor: 8.311

10.  LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes.

Authors:  K R Feingold; C Grunfeld; M Pang; W Doerrler; R M Krauss
Journal:  Arterioscler Thromb       Date:  1992-12
View more
  8 in total

1.  Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.

Authors:  Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien
Journal:  AIDS       Date:  2015-07-17       Impact factor: 4.177

2.  Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.

Authors:  Sophia Swanson; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael W Plankey; Carl Grunfeld; William M Rosenberg; Marion G Peters; Phyllis C Tien
Journal:  J Infect Dis       Date:  2015-11-29       Impact factor: 5.226

3.  Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.

Authors:  Kerry Townsend; Eric G Meissner; Sreetha Sidharthan; Maureen Sampson; Alan T Remaley; Lydia Tang; Anita Kohli; Anu Osinusi; Henry Masur; Shyam Kottilil
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-15       Impact factor: 2.205

4.  Hepatitis C Virus-Associated Alterations in Lipid and Lipoprotein Levels: Helpful or Harmful to the Heart?

Authors:  Phyllis C Tien
Journal:  Clin Infect Dis       Date:  2017-08-15       Impact factor: 9.079

5.  Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Juan Berenguer; Elena Rodríguez-Castellano; Ana Carrero; Miguel A Von Wichmann; Marta Montero; María J Galindo; Josep Mallolas; Manuel Crespo; María J Téllez; Carmen Quereda; José Sanz; Carlos Barros; Cristina Tural; Ignacio Santos; Federico Pulido; Josep M Guardiola; Rafael Rubio; Enrique Ortega; María L Montes; Juan J Jusdado; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García
Journal:  Hepatology       Date:  2017-06-22       Impact factor: 17.425

6.  Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.

Authors:  Alejandro Alvaro-Meca; Juan Berenguer; Asunción Díaz; Dariela Micheloud; Teresa Aldámiz-Echevarría; Chiara Fanciulli; Salvador Resino
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

7.  Serological Evidence of Hepatitis B and E and Dengue Coinfection in Chadian Patients and Impact on Lipidemia Profile.

Authors:  Alexandre Kanga Djasrabe; Borris Rosnay Tietcheu Galani; Moussa Mahamat Ali; Fissou Henry Yandai; Bessimbaye Nadlaou; Mayann Habkreo; Nicolas Yanou Njintang
Journal:  Int J Hepatol       Date:  2022-09-16

8.  HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".

Authors:  Payal Kohli; Peter Ganz; Yifei Ma; Rebecca Scherzer; Sophia Hur; Bernard Weigel; Carl Grunfeld; Steven Deeks; Scott Wasserman; Rob Scott; Priscilla Y Hsue
Journal:  J Am Heart Assoc       Date:  2016-04-29       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.